MX2021008076A - Terapia de combinacion de aglutinantes de fosfato y vitamina k. - Google Patents

Terapia de combinacion de aglutinantes de fosfato y vitamina k.

Info

Publication number
MX2021008076A
MX2021008076A MX2021008076A MX2021008076A MX2021008076A MX 2021008076 A MX2021008076 A MX 2021008076A MX 2021008076 A MX2021008076 A MX 2021008076A MX 2021008076 A MX2021008076 A MX 2021008076A MX 2021008076 A MX2021008076 A MX 2021008076A
Authority
MX
Mexico
Prior art keywords
vitamin
combination therapy
phosphate binders
phosphate
combination
Prior art date
Application number
MX2021008076A
Other languages
English (en)
Inventor
Daniel H Rosenbaum
Lee M Techner
Original Assignee
Nattopharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nattopharma As filed Critical Nattopharma As
Publication of MX2021008076A publication Critical patent/MX2021008076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un método para el tratamiento de una enfermedad renal crónica, el cual incluye la administración a un sujeto que lo necesite, de una combinación de una vitamina K y un aglutinante de fosfato.
MX2021008076A 2019-01-04 2020-01-03 Terapia de combinacion de aglutinantes de fosfato y vitamina k. MX2021008076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962788523P 2019-01-04 2019-01-04
PCT/US2020/012181 WO2020142687A1 (en) 2019-01-04 2020-01-03 Combination therapy of phosphate binders and vitamin k

Publications (1)

Publication Number Publication Date
MX2021008076A true MX2021008076A (es) 2021-12-10

Family

ID=71404653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008076A MX2021008076A (es) 2019-01-04 2020-01-03 Terapia de combinacion de aglutinantes de fosfato y vitamina k.

Country Status (10)

Country Link
US (2) US20220079891A1 (es)
EP (1) EP3890831A4 (es)
JP (1) JP2022516567A (es)
KR (1) KR20210111789A (es)
CN (1) CN113260417A (es)
AU (1) AU2020204692A1 (es)
BR (1) BR112021013046A2 (es)
CA (1) CA3125292A1 (es)
MX (1) MX2021008076A (es)
WO (1) WO2020142687A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115317494B (zh) * 2022-07-22 2024-02-13 康瑞鑫(天津)药物研究院有限公司 高磷酸盐结合力的蔗糖氢氧化氧铁及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
WO2016131993A2 (en) * 2015-02-20 2016-08-25 Vitak B.V. Vitamin k and capillary function
JP2021527129A (ja) * 2018-06-08 2021-10-11 エピゾン・ファーマ・インコーポレイテッドＥｐｉｚｏｎ Ｐｈａｒｍａ， Ｉｎｃ． カルシフィラキシスを予防または治療するための方法および組成物

Also Published As

Publication number Publication date
AU2020204692A1 (en) 2021-07-29
US20220079891A1 (en) 2022-03-17
CA3125292A1 (en) 2020-07-09
EP3890831A1 (en) 2021-10-13
WO2020142687A1 (en) 2020-07-09
BR112021013046A2 (pt) 2021-09-21
CN113260417A (zh) 2021-08-13
KR20210111789A (ko) 2021-09-13
EP3890831A4 (en) 2022-09-21
US20200215000A1 (en) 2020-07-09
JP2022516567A (ja) 2022-02-28

Similar Documents

Publication Publication Date Title
MX2020003719A (es) Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer.
PH12017501818A1 (en) Fgfr/pd-1 combination therapy for the treatment of cancer
MX2020009773A (es) Terapia de combinacion.
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
NZ716473A (en) Diagnosis and therapy of cancer involving cancer stem cells
MX2019014274A (es) Metodo de tratamiento.
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2020001727A (es) Terapia de combinacion.
PH12020551447A1 (en) Antibodies
MX2019013862A (es) Terapia de combinacion.
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
MX2021008076A (es) Terapia de combinacion de aglutinantes de fosfato y vitamina k.
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2022000394A (es) Combinaciones terapeuticas de paclitaxel oralmente administrado y un inhibidor de la bomba de p-glicoproteina (p-gp) para el tratamiento del cancer.
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
MX2024008740A (es) Anticuerpo humanizado que tiene especificidad de union por la integrina \03b14\03b27 humana para usarse en la prevencion de la enfermedad del injerto contra huesped de grado iii o iv.
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.